Articles
Three new drugs are in the pipeline to treat human epidermal growth factor receptor (HER) type 2-positive metastatic breast cancer (MBC). Two appear to have the potential to provide incremental gains, and one looks like a game changer.
Characterized by thrombocytopenia and bleeding manifestations, particularly mucocutaneous, idiopathic thrombocytopenic purpura (ITP) is an autoimmune disorder seen in both adults and children. Although the majority of ITP cases in children are considered acute and typically resolve within 6 months often without therapy, adult ITP is generally chronic and requires therapeutic interventions to raise platelet counts.1
April 2010 was the second National Safe Handling Month, a campaign designed to further education about the risks associated with handling hazardous drugs and safety measures that can prevent exposure to these agents. The initiative was supported by an unrestricted educational grant provided by Carmel Pharma, Inc, the maker of the PhaSeal closed-system drug transfer device (CSTD) and included regional and national educational activities.
CEP17 Breast Cancer Tumors Are More Likely to Respond to Anthracyclines
BARCELONA—Breast cancer patients with the chromosome enumeration probe 17 (CEP17) alpha satellite abnormality are more likely to have good outcomes from chemotherapy involving anthracycline antibiotics than women without the abnormality, according to new data released at the Seventh European Breast Cancer Conference.
President Obama guaranteed Americans that after health reform became law they could keep their insurance plans and their doctors. It’s clear that this promise cannot be kept. Insurers and physicians are already reshaping their businesses as a result of Mr. Obama’s plan.
Opened in 1989, the Comprehensive Cancer Center (CCC) at Desert Regional Medical Center was the first multidisciplinary outpatient cancer program in the Palm Springs, California, area. The CCC represents the collaboration of the multispecialty regional medical center with Aptium Oncology, a national provider of oncology management and consulting services. The CCC now employs 120 healthcare professionals and provides a full range of services, including screening, diagnosis, treatment, and follow-up care under one roof.
Investigators are reporting favorable results with a program that allows a hospital pharmacy to employ pharmacists who are not able to work onsite in the hospital.
Pharmacists can make a significant contribution to an overseas medical mission. In fact, the participation of a pharmacist on a recent mission to rural Kenya led by a California-based hospital proved to be so invaluable that all future missions to that region plan to have a pharmacist onboard.
Researchers are calling for increased awareness of the potential for chemotherapy-induced visual disturbances.
Chemotherapy appears to be associated with a statistically significant decrease in the relative risk of prostate cancer-specific mortality among older men with stage IV prostate cancer who are receiving androgen-deprivation therapy (ADT), according to a new study.